Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00109512 · ClinicalTrials.gov registry record · Phase 2

Endometriosis Trial: Study of NBI-56418 in Endometriosis

A Phase 2 study of Endometriosis, sponsored by Abbott.

Completed
Registry status
Phase 2
Development phase
76
Enrollment target
15
Study locations

NCT00109512 is a Phase 2 study of Endometriosis that has completed, run by Abbott. The registered enrollment target is 76 participants, below the 263-participant average among 48 other Endometriosis trials with a reported enrollment target (71% lower). The trial reports 15 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00109512, a Phase 2 study of Endometriosis, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 2
Development phase
76 participants
Enrollment target
15
Study locations

Study Summary

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in a 1:1:1 ratio. Study drug was administered once daily for 12 weeks. After the last dose at the end of Week 12, follow-up continued every 4 weeks for 12 weeks.

Conditions Studied

Endometriosis

Interventions

  • DRUG placebo
  • DRUG NBI-56418 (GnRH antagonist)

Study Locations (15)

Illinois

  • Site Reference ID/Investigator# 56270 - Champaign
  • Site Reference ID/Investigator# 56273 - Chicago
  • Site Reference ID/Investigator# 56269 - Oak Brook
  • Site Reference ID/Investigator# 56271 - Peoria

California

  • Site Reference ID/Investigator# 55210 - San Diego
  • Site Reference ID/Investigator# 55214 - San Ramon

Virginia

  • Site Reference ID/Investigator# 56274 - Richmond
  • Site Reference ID/Investigator# 55212 - Virginia Beach

Arizona

  • Site Reference ID/Investigator# 56266 - Phoenix

Florida

  • Site Reference ID/Investigator# 56267 - Clearwater

Kentucky

  • Site Reference ID/Investigator# 56272 - Louisville

North Carolina

  • Site Reference ID/Investigator# 55213 - Winston-Salem

Texas

  • Site Reference ID/Investigator# 55211 - Arlington

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2005-04
Est. Completion 2006-06
Phase Phase 2

Sponsor

Abbott

181 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00109512

The ClinicalTrials.gov registry entry for NCT00109512 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 263-participant average among 48 other Endometriosis trials with a reported enrollment target (71% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Endometriosis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00109512 reports 15 study locations spanning 10 distinct geographic areas - top geographies include Illinois, California, Virginia.

Frequently Asked Questions

What is clinical trial NCT00109512 about?

NCT00109512 is a clinical study titled "Endometriosis Trial: Study of NBI-56418 in Endometriosis". This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with subjects randomized to one of three treatment groups, placebo, 75 mg and 150 mg in a 1:1:1 ratio. Study drug was administered once daily for 12 weeks. After the last dose at the end of Week 12, f...

What is the current status of trial NCT00109512?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2005-04. Estimated completion is 2006-06.

What conditions does trial NCT00109512 study?

This clinical trial studies the following conditions: Endometriosis.

What interventions are being tested in trial NCT00109512?

The interventions under investigation include: placebo (DRUG), NBI-56418 (GnRH antagonist) (DRUG).

Who is sponsoring clinical trial NCT00109512?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00109512 being conducted?

This trial has 15 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometriosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometriosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.